Business Context and Reporting Period
This Form 8-K Current Report was filed by Aldeyra Therapeutics, Inc. (ALDX) on April 17, 2025. The report discloses corporate governance changes, specifically the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors to eight.
- New Director Election: William (Chip) Clark was elected as a Class I director, with his term expiring at the 2027 annual meeting of stockholders.
- Independence: The Board determined Mr. Clark is an independent director in accordance with SEC and Nasdaq rules.
Compensatory Arrangements and Governance
In connection with his election, Mr. Clark received the following compensation under the Company's non-employee director program:
- Initial Stock Option: Granted 76,760 shares of common stock with an exercise price equal to the closing price on April 17, 2025. The option vests ratably in annual installments over three years.
- Annual Cash Fee: $40,000 per year for service as a director.
- Annual Stock Option Grant: Eligible to receive an option to purchase approximately $130,000 of common stock upon the conclusion of each annual meeting. These grants vest in full on the one-year anniversary of the grant date.
- Indemnification: Mr. Clark entered into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the closing stock price of ALDX on April 17, 2025, to determine the exercise price of the initial 76,760 share option grant.
- Review the attached Press Release (Exhibit 99.1) for additional context on Mr. Clark's background and qualifications.
- Confirm the total number of outstanding shares and potential dilution impact from the new director grants.
- Check the Company's Proxy Statement for the 2024 Annual Meeting for the full details of the non-employee director compensation program.